Company Overview
- Website
- kestreltherapeutics.com
- Employees
- 9
- Industry
- BioTech/Drugs
- SIC Code
-
8731 - Commercial Physical and Biological Research
Financials & Stats
Revenue
$10B
Recent News & Media
Kestrel Therapeutics describes new GTPase KRAS inhibitors
- Jul 2, 2025
- bioworld.com
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer
- Mar 7, 2025
- aacrjournals.org
Targeting fusion oncoproteins in childhood cancers: challenges and future opportunities for developing therapeutics
- Nov 13, 2024
- pmc.ncbi.nlm.nih.gov
Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer
- Sep 16, 2024
- aacrjournals.org
15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1)
- Jul 25, 2024
- pmc.ncbi.nlm.nih.gov
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance
- Jul 11, 2024
- nature.com
Company Leadership
Kestrel Therapeutics Industry Tags
Companies Similar to Kestrel Therapeutics
Analyze industry trends and opportunities by examining competitors and companies comparable to Kestrel Therapeutics, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 10M | 59 | Boston, MA | ||
| 10M | 27 | Cambridge, MA | 2010 | |
| 10M | 23 | Waltham, MA | 1999 | |
| 10M | 2 | Boston, MA | ||
| 10M | 46 | Woburn, MA |